Caplin Point Laboratories, through its wholly owned subsidiary Caplin Point Far East Limited based in Hong Kong, has entered into a Share Purchase Agreement dated June 3, 2025, to acquire the entire shareholding in Triwin Pharma S.A. DE C.V, a company based in Mexico. Triwin Pharma currently has a share capital of 50,000 equity shares with a face value of one Mexican Peso each and has reported no turnover as of March 31, 2025.
This acquisition aligns with Caplin Point’s objective of establishing a local presence in the Mexican pharmaceutical market. Triwin Pharma will function as the front-end entity for sales, marketing, and distribution of products manufactured by Caplin Point Laboratories and its subsidiaries. This includes operations related to tender-based and direct sales within Mexico.
The acquisition does not require specific prior regulatory approvals. Once the agreed consideration is paid within 30 days of signing the agreement, Triwin Pharma will become a wholly owned subsidiary of Caplin Point Far East Limited and a step-down subsidiary of Caplin Point Laboratories. The transaction will be executed through normal banking channels at face value.
Triwin Pharma was incorporated on February 12, 2019, and has not recorded any turnover in the last three financial years. The move is part of Caplin Point’s broader strategy to enhance market access in Latin America by replicating stock-and-sale distribution models that have been implemented in other regional markets.
